MAX Chat
Company Analysis Xiamen Amoytop Biotech Co., Ltd.
1. Summary
Advantages
- The stock's return over the last year (23.01%) is higher than the sector average (0%).
- The company's current efficiency (ROE=37.37%) is higher than the sector average (ROE=2.65%)
Disadvantages
- Price (71.9 Β₯) is higher than fair price (34.71 Β₯)
- Dividends (0%) are below the sector average (0.3202%).
- Current debt level 0.3311% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Xiamen Amoytop Biotech Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.6% | 1.5% | -1.4% |
| 90 days | -3.2% | 2.3% | 13.8% |
| 1 year | 23% | 0% | 45.2% |
688278 vs Sector: Xiamen Amoytop Biotech Co., Ltd. has outperformed the "Healthcare" sector by 23.01% over the past year.
688278 vs Market: Xiamen Amoytop Biotech Co., Ltd. has significantly underperformed the market by -22.15% over the past year.
Stable price: 688278 is not significantly more volatile than the rest of the market on "Shanghai Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 688278 with weekly volatility of 0.4425% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (71.9 Β₯) is higher than the fair price (34.71 Β₯).
Price is higher than fair: The current price (71.9 Β₯) is 51.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (36.06) is lower than that of the sector as a whole (118.32).
P/E vs Market: The company's P/E (36.06) is lower than that of the market as a whole (69.6).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (11.69) is higher than that of the sector as a whole (5.73).
P/BV vs Market: The company's P/BV (11.69) is higher than that of the market as a whole (3.04).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (10.59) is lower than that of the sector as a whole (16.05).
P/S vs Market: The company's P/S indicator (10.59) is higher than that of the market as a whole (6.18).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (42.91) is higher than that of the sector as a whole (16.62).
EV/Ebitda vs Market: The company's EV/Ebitda (42.91) is higher than that of the market as a whole (17.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 121.99% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (121.99%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (8.87%).
5.4. ROE
ROE vs Sector: The company's ROE (37.37%) is higher than that of the sector as a whole (2.65%).
ROE vs Market: The company's ROE (37.37%) is higher than that of the market as a whole (6.13%).
5.5. ROA
ROA vs Sector: The company's ROA (30.62%) is higher than that of the sector as a whole (3.24%).
ROA vs Market: The company's ROA (30.62%) is higher than that of the market as a whole (3.23%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.3202%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.8.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 4 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (20.15%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
